Innovating Works

SUBLIMITY

Desconocido
SAMPA: Scale up of an Advanced Manufacturing process to produce a Pharmaceutical product Application SAMPA... SUBLIMITY THERAPEUTICS LIMITED tramitó un H2020: H2020-SMEInst-2014-2015 Sublimity Therapeutics has developed an innovative product, ST-0529, to treat patients with moderate-severe Ulcerative Colitis, a disease th...
2015-06-21 - 2020-04-30 | Financiado
HELICOVAXOR: Development of an oral Helicobacter Pylori vaccine SUBLIMITY THERAPEUTICS LIMITED tramitó un FP7: Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly...
Financiado
ADITEC: Advanced Immunization Technologies SUBLIMITY THERAPEUTICS LIMITED participó en un FP7: Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious...
Financiado
PARTICLE-PRO: Development of a hybrid process analytical technology to characterise the physical and chemical prop... SUBLIMITY THERAPEUTICS LIMITED participó en un FP7: Particles and granules play a key role in process efficacy and final product quality for numerous industries including pharmaceuticals, food...
Financiado
TRANS-INT: New Oral Nanomedicines Transporting Therapeutic Macromolecules across the Intestinal Barrier SUBLIMITY THERAPEUTICS LIMITED participó en un FP7: Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies hav...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.